Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (471-480 of 527) with videos related to

Pageof 53
Sort By:
Journal of Gastroenterology and Hepatology|March 13, 2024
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational studyTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
Alimentary Pharmacology & Therapeutics|January 4, 2024
Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic responseJung Eun Park, Vy H Nguyen, Pei-Chien Tsai, et al.
The Kaohsiung Journal of Medical Sciences|October 27, 2023
Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogsTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
Hepatology International|August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
American Journal of Cancer Research|August 15, 2022
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort studyHung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, et al.
Alimentary Pharmacology & Therapeutics|May 21, 2025
Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B StudyRui Huang, Ai-Thien Do, Hidenori Toyoda, et al.
The American Journal of Gastroenterology|March 30, 2020
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Chung-Feng Huang, Hsueh-Chou Lai, Chi-Yi Chen, et al.
Scientific Reports|March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritisWei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Hepatology International|November 25, 2021
Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B studyLung-Yi Mak, Joseph Hoang, Dae Won Jun, et al.
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Pageof 53

Showing results (471-480 of 527) with videos related to

Sort By:
Pageof 53
Journal of Gastroenterology and Hepatology|March 13, 2024
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational studyTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
Alimentary Pharmacology & Therapeutics|January 4, 2024
Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic responseJung Eun Park, Vy H Nguyen, Pei-Chien Tsai, et al.
The Kaohsiung Journal of Medical Sciences|October 27, 2023
Pretreatment gamma-glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogsTyng-Yuan Jang, Po-Cheng Liang, Dae Won Jun, et al.
Hepatology International|August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
American Journal of Cancer Research|August 15, 2022
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort studyHung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, et al.
Alimentary Pharmacology & Therapeutics|May 21, 2025
Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL-B StudyRui Huang, Ai-Thien Do, Hidenori Toyoda, et al.
The American Journal of Gastroenterology|March 30, 2020
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Chung-Feng Huang, Hsueh-Chou Lai, Chi-Yi Chen, et al.
Scientific Reports|March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritisWei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Hepatology International|November 25, 2021
Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B studyLung-Yi Mak, Joseph Hoang, Dae Won Jun, et al.
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Pageof 53